Search clinical trials for: Part2 : Placebo of OPS-2071

Total 29142 results

Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
Otsuka Beijing Research Institute

Recruiting

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

China
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis

Bacterial Enteritis

Korea, Republic of, Singapore, Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

Bacterial Enteritis

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
IQVIA Pvt. Ltd

Terminated

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

Crohn's Disease

United States, Poland
Amytrx Therapeutics, Inc.
Amarex Clinical Research

Completed

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)

COVID-19

Philippines
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-208

Androgenetic Alopecia

Korea, Republic of
Huahui Health

Completed

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

COVID-19

China
Ono Pharmaceutical Co. Ltd

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers

Osteoarthritis

Denmark, United Kingdom
Imperial College London

Withdrawn

Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Healthy Participants

United States
GLWL Research Inc.

Terminated

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Diabetes Mellitus, Type 2

United States
Chiesi Farmaceutici S.p.A.

Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD (CHF6297 FIH)

Chronic Obstructive Pulmonary Disease

United Kingdom
Mineralys Therapeutics Inc.

Completed

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension (Target-HTN)

Hypertension, Renal

United States
Addpharma Inc.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
GlaxoSmithKline

Terminated

A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United Kingdom
University of Maryland, Baltimore

Withdrawn

Brain Biomarker on Inflammation Response (LPS)

Schizophrenia

United States
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Lupus Nephritis

France, Spain, Israel, Turkey, United States, Germany, India, Hungary, Malaysia, Portugal, Brazil, China, Puerto Rico, Hong Kong, Mexico, Singapore
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (CHF6333 FIH)

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Belgium
Shire

Completed

Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

Migraine Headache

United States
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Kowa Company, Ltd.

Completed

A Study to Evaluate the Safety of K-755 in Healthy Volunteers

Healthy

Australia
ReAlta Life Sciences, Inc.
Premier Research Group plc

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia (STAR)

Hypoxic-Ischemic Encephalopathy

United States
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Oryzon Genomics S.A.
Alzheimer's Drug Discovery Foundation

Completed

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (ETHERAL-US)

Mild to Moderate Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Study of LY3143753 and LY3185643 in Healthy Participants

Healthy

United Kingdom
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
ReAlta Life Sciences, Inc.

Recruiting

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acute Exacerbation of Chronic Obstructive Pulmonary Disease

United States
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Phase I Study of SHR -2001 in Healthy Subjects

Healthy

China
Valo Health, Inc.

Withdrawn

Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) (RESTORE)

Myocardial Infarction
Radboud University Medical Center

Completed

The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response (LPS-Fluenz)

Innate Immune Response | Immune Tolerance
Kissei Pharmaceutical Co., Ltd.

Completed

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Intellia Therapeutics
Regeneron Pharmaceuticals

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Australia, United Kingdom, New Zealand
Elixiron Immunotherapeutics Inc.
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Terminated

An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH)

Alzheimer's Disease
AceLink Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers

Autosomal Dominant Polycystic Kidney

Australia
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Tension-Type Headache

United States
Indivior Inc.

Completed

Buprenorphine-Fentanyl Interaction Study

Healthy | Opioid Use

Netherlands
PegBio Co., Ltd.

Completed

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Type2 Diabetes Mellitus

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Acute Schizophrenia

United States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

Atopic Dermatitis

Japan
ReAlta Life Sciences, Inc.

Completed

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

Healthy Volunteer

Canada
Mereo BioPharma
Novartis

Terminated

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

Acute Kidney Injury

Taiwan, United States, Israel

3

Subscribe